Presbyopia is an age-related condition that commonly appears in people aged 40 to 50. As the eye ages, loss of lens elasticity results in an inability to focus on nearby objects. Presbyopia affects close to 2 billion worldwide, including over 100 million people in the United States. Like glaucoma, presbyopia’s prevalence is expected to rise as the average age of the population increases over time.
Individuals with presbyopia use reading glasses, contact lenses, and in some cases, surgical interventions, but there are no currently approved drug therapies for presbyopia. There are several drawbacks to reading glasses. For example, presbyopia only affects near vision, so reading glasses must be put on and taken off throughout the day. Contact lenses for presbyopia may cause eye strain, night vision disturbances, and other side effects. Eye drops are considered to be the “holy grail” alternative to corrective devices for presbyopia.
Presbyopia is a large unmet market, where pupil aperture management such as Nyxol’s approach is an intense area of focus. Nyxol is a potential treatment alone or in combination for presbyopia, based on its ability to reduce pupil diameter and improve visual acuity. The goal is to achieve a target pinhole size, which will result in clearer near vision.